Shattering the Amyloid Illusion: The Microbial Enigma of Alzheimer’s Disease Pathogenesis—From Gut Microbiota and Viruses to Brain Biofilms

Microorganisms, Journal Year: 2025, Volume and Issue: 13(1), P. 90 - 90

Published: Jan. 5, 2025

For decades, Alzheimer's Disease (AD) research has focused on the amyloid cascade hypothesis, which identifies amyloid-beta (Aβ) as primary driver of disease. However, consistent failure Aβ-targeted therapies to demonstrate efficacy, coupled with significant safety concerns, underscores need rethink our approach AD treatment. Emerging evidence points microbial infections environmental factors in pathoetiology. Although a definitive causal link remains unestablished, collective is compelling. This review explores unconventional perspectives and emerging paradigms regarding involvement pathogenesis, emphasizing gut-brain axis, brain biofilms, oral microbiome, viral infections. Transgenic mouse models show that gut microbiota dysregulation precedes Aβ accumulation, signaling pathways. Viral like Herpes Simplex Virus Type 1 (HSV-1) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may lead by modulating host processes immune system. peptide's antimicrobial function response infection might inadvertently promote AD. We discuss potential microbiome-based promising strategies for managing potentially preventing progression. Fecal transplantation (FMT) restores balance, reduces improves cognition preclinical models. Probiotics prebiotics reduce neuroinflammation plaques, while antiviral targeting HSV-1 vaccines shingles vaccine mitigate pathology. Developing effective treatments requires standardized methods identify measure patients, enabling personalized address individual contributions pathogenesis. Further needed clarify interactions between microbes Aβ, explore bacterial interplay, understand their broader effects translate these insights into clinical interventions.

Language: Английский

---

Exploring the microbiome-gut-testis axis in testicular germ cell tumors

Frontiers in Cellular and Infection Microbiology, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 9, 2025

The microbiome-gut-testis axis has emerged as a significant area of interest in understanding testicular cancer, particularly germ cell tumors (TGCTs), which represent the most common malignancy young men. interplay between gut and microbiomes is hypothesized to influence tumorigenesis reproductive health, underscoring complex role microbial ecosystems disease pathology. encompasses interactions microbiome, systemic immune modulation, local microenvironment testis. Dysbiosis or may contribute altered responses, inflammation, hormonal imbalances, potentially playing pathogenesis TGCTs. Concurrently, seminal have been linked variations sperm quality, fertility potential, possibly cancer susceptibility, need for further evaluation. This review explores emerging context highlighting its implications onset, progression, treatment efficacy, toxicity. Identifying potential biomarkers, followed by microbiota modulation restore balanced community, might offer novel supportive strategy improving efficacy refractory TGCT patients while reducing chemotherapy-induced We suggest better association dysregulated environments TGCTs emphasizes pathways microbiome cancer.

Language: Английский

---

The Interplay of Nutrition, the Gut Microbiota and Immunity and Its Contribution to Human Disease

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 329 - 329

Published: Jan. 31, 2025

Nutrition, the gut microbiota and immunity are all important factors in maintenance of health. However, there is a growing realization complex interplay between these elements coalescing nutrition-gut microbiota-immunity axis. This regulatory axis critical for health with disruption being implicated broad range diseases, including autoimmune disorders, allergies mental disorders. new perspective continues to underpin number innovative therapeutic strategies targeting different this treat relevant diseases. review describes inter-relationships nutrition, immunity. It then details several human diseases where has been identified presents examples how various may be targeted therapeutically as alternate treatment

Language: Английский

---

Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium

Gut, Journal Year: 2025, Volume and Issue: unknown, P. gutjnl - 334501

Published: Feb. 26, 2025

Objective Live biotherapeutic products (LBPs) are biological composed of living micro-organisms, developed to prevent, treat, or cure diseases. Examples include cultured strains Akkermansia muciniphila and Christensenella minuta , as well treatments using purified Firmicutes spores for recurrent Clostridioides difficile infections. There is a need guidelines over the increasing interest in developing LBPs. A panel microbiome experts from Asia-Pacific countries articulates their perspectives on key considerations LBP development. Design Experts research, microbiology, gastroenterology, internal medicine biotherapeutics industry were invited form panel. During 2023 Inauguration Conference Microbiota Consortium, an organised, iterative roundtable discussion was conducted build expert consensus critical issues surrounding development LBP. Results The statements organised into three main aspects: (a) rationales development, (b) preclinical studies (c) preparation clinical studies. strongly recommended prioritise human-derived food-sourced with indications based efficacy shown Preclinical evaluation should involve thorough screening, genotyping phenotyping, comprehensive vitro animal assess functional mechanisms microbiological safety. Rigorous cell banking practices genetic monitoring essential ensure product consistency safety throughout manufacturing process. Clinical trials, including postmarketing surveillance, must be carefully designed closely monitored, robust risk management protocols place. Conclusions approached strong emphasis evaluation, relevance, scientific at every stage. These measures safety, effectiveness long-term success product.

Language: Английский

---

Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Nov. 5, 2024

Faecal/intestinal microbiota transplant (FMT/IMT) is an efficacious treatment option for recurrent Clostridioides difficile infection, which has prompted substantial interest in FMT's potential role the management of a much broader range diseases associated with gut microbiome. Despite its promise, success rates FMT these other settings have been variable. This review critically evaluates current evidence on impact clinical, biological, and procedural factors upon therapeutic efficacy FMT, identifies areas that remain nebulous. Due to some factors, optimal approach remains unclear; example, preferred timing administration heavily antibiotic-exposed hematopoietic cell recipient not standardized, arguments can be made alternate directions. We explore how may more informed selection donors, matching donors recipients, aspects clinical care recipients. includes consideration microbiome composition functionality strategically inform donor criteria. Furthermore, we most productive advances within space are those where translational outcomes assessed together, this model used productively recent years better understand contribution human disease, start process toward development targeted therapeutics.

Language: Английский

---

A Review of the Consequences of Gut Microbiota in Neurodegenerative Disorders and Aging

Brain Sciences, Journal Year: 2024, Volume and Issue: 14(12), P. 1224 - 1224

Published: Dec. 3, 2024

Age-associated alterations in the brain lead to cognitive deterioration and neurodegenerative disorders (NDDs). This review with a particular focus on Alzheimer’s disease (AD), emphasizes burgeoning significance of gut microbiota (GMB) neuroinflammation its impact gut–brain axis (GBA), communication conduit between central nervous system (CNS). Changes microbiome, including diminished microbial diversity prevalence pro-inflammatory bacteria, are associated AD pathogenesis. Promising therapies, such as fecal transplantation (FMT), probiotics, prebiotics, may restore health enhance performance. Clinical data remain insufficient, necessitating further research elucidate causes, therapy, consider individual variances. integrative approach yield innovative therapies aimed at GMB improve function older people.

Language: Английский

---

Unlocking the healthy human microbiome: Redefining core microbial signatures

Acta Pharmaceutica Sinica B, Journal Year: 2025, Volume and Issue: 15(2), P. 1189 - 1192

Published: Jan. 7, 2025

Language: Английский

---

THE ROLE OF ALLULOSE AND SUGAR ALCOHOLS IN GUT MICROBIOTA MODULATION AND METABOLIC HEALTH: A REVIEW

Universal Journal of Pharmaceutical Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Allulose and sugar alcohols, like erythritol xylitol, are low-calorie sweeteners gaining attention for their potential to positively influence metabolic health. This brief review explores how these can shape the gut microbiota. Acting as prebiotics, they foster growth of beneficial bacteria stimulate production short-chain fatty acids. These effects may contribute improved insulin sensitivity, reduced inflammation a stronger barrier. However, excessive alcohol intake lead digestive discomfort. Further research is needed assess long-term impact on microbiota health, well interactions with other dietary factors. By understanding intricate relationship between sweeteners, it will be possible develop well-informed guidelines optimize health well-being. Peer Review History: Received 5 October 2024; Reviewed 12 November; Accepted 22 December; Available online 15 January 2025 Academic Editor: Prof. Dr. Gorkem Dulger, Duzce University, Turkey, [email protected] Average marks at initial stage: 5.0/10 publication 7.0/10

Language: Английский

---

From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease

Microorganisms, Journal Year: 2025, Volume and Issue: 13(2), P. 241 - 241

Published: Jan. 23, 2025

The gut microbiota has emerged as a critical player in metabolic and liver health, with its influence extending to the pathogenesis progression of steatotic diseases. This review delves into gut-liver axis, dynamic communication network linking microbiome through metabolic, immunological, inflammatory pathways. Dysbiosis, characterized by altered microbial composition, contributes significantly development hepatic steatosis, inflammation, fibrosis via mechanisms such barrier dysfunction, metabolite production, systemic inflammation. Dietary patterns, including Mediterranean diet, are highlighted for their role modulating microbiota, improving axis integrity, attenuating injury. Additionally, emerging microbiota-based interventions, fecal transplantation bacteriophage therapy, show promise therapeutic strategies disease. However, challenges population heterogeneity, methodological variability, knowledge gaps hinder translational application current findings. Addressing these barriers standardized approaches integrative research will pave way microbiota-targeted therapies mitigate global burden

Language: Английский

---

Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework

The EPMA Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

Language: Английский

---